
## **CLAIMS**

- 1. The use of a furin inhibitor in the manufacture of a medicament for reducing scarring during the healing of wounds or reducing fibrosis in the treatment of fibrotic conditions wherein the medicament is topically applied to the site of a wound or fibrotic disorder.
- 2. The use according to claim 1 wherein the inhibitor is a serine protease inhibitor.
- 3. The use according to any preceding claim wherein the inhibitor is lipid soluble.
- 4. The use according to claim 2 wherein the inhibitor is a peptidyl chloroalkylketone having a peptide moiety which mimics at least one convertase enzyme cleavage site.
- 5. The use according to claim 2 wherein the inhibitor is decanoyl-RVKR-cmk.
- 6. The use according to claim 1 or claim 2 wherein the inhibitor is water soluble.
- 7. The use according to claim 6 wherein the inhibitor is hexa-arginine.
- 8. The use according to any preceding claim for treating wounds to inhibit or prevent scar formation.
- 9. The use according to claim 8 for inhibiting or preventing scarring of the eye, nervous tissue or intestines.
- 10. The use according to claim 8 for inhibiting or preventing dermal scarring.





- 11. The use according to claim 8 for inhibiting or preventing scarring following a burn.
- 12. The use according to any one of claims 1 to 7 for reducing fibrosis in the treatment of fibrotic conditions.
- 13. The use according to claim 12 wherein the fibrotic condition is a fibrotic disorder selected from glomerulonephritis, cirrhosis of the liver, fibrocytic disease, adhesions or restenosis.